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corticoesteroids, malabsortive disorders, chronic systemic disorders such as nephropathies or hematologic diseases, etc. The patients or their legal tutors signed the Informed Consent in order to participate in the study. The average daily calcium intake was collected through the Spanish INDICAD 2001 study survey, together with a comprehensive anamnesis. If patients or their family reported taking food not included in the survey, its calcium content were consulted in the Spanish Food Composition Database published by the BEDCA Network of the Ministry of Health Science and Innovation Results: Data were collected from 50 patients, with a mean age of 9.2 years (2-20), 28 (56%) female, 86% Caucasian, 6% Arab, 2% Asian and 6% Latin. The most frequent diagnoses were: Food intolerances/malabsorption: 32%, nephropathies: 22%, JIA: 16%, vasculitis: 10%, other inflammatory diseases: 8%. 42% had received systemic corticosteroids at some point, and 16% were receiving corticosteroids at present. Average daily calcium intake was 718 mg/d. They were divided by age groups, attending to daily calcium needs per group. In Table 1 Only 3 children with low calcium intake were taking supplements.A decrease in calcium RDA adherence was observed with increasing age, statistically significant (p=0.009). There was also a lower calcium intake in the non-Caucasians compared to Caucasians statistically significant (p=0.044), which was not associated with age.
Conclusions: Calcium intake in the population under 21 years old with at least 1 risk factor for developing low bone mass/osteoporosis is lower than recommended. In addition, recommendations are based on the physiological needs of the healthy population and it could be expected to be insufficient for those with chronic diseases. It should be noted that calcium intake in the groups with higher requirements (adolescents and young people) is lower, with a reduction in the proportion of patients who meet the compliance with the RDA as age increases. Studies with a larger population are needed to ratify these results together with serum calcidiol levels . This retrospective cost study evaluated the data of these patients and calculated the direct cost for the follow-up period. Clinical data was collected from patient files that were in department's archive and cost data was gathered from Probel Hospital Information Management system. Patient data form covering sociodemographic and clinical information, patient drug form and annual medical cost form was filled out for each patient. Results: 58.5% (n=62) of patients was female and 41.5% (n=44) was male. The mean age was 12.0±4.3 years. 34.0% (n=36) of patients was oligoarticular type, 28.3% (n=30) was poliarticular type, 22.6% (n=24) was enthesitis related arthritis (ERA), 8,5% (n=9) was psoriatic type and 6.6% (n=7) was systemic type. The cost of medication counted for 88.3% (453244.94 TL) of total direct annual cost. Total direct medical cost was highest for ERA (n=7742.55±9891 TL). While the annual cost was calculated as 10451 TL per person for biologic using patients, for the patients using non-biologic treatments it was determined as 1472 TL per person. 1 TL=0.32 1 TL =0.35 $ Conclusions: Medication is responsible for most of the total direct medical cost in patients with JIA. Our results showed concordance with previous studies on the subject. This situation could be attributed to biologic agents that are being used in treatment in recent years. More prospective studies on the effectiveness of cost of treatment, with greater amount of patient and more homogenous subgroups are needed. Analysis showed that poor response in all JIA categories was mainly associated with demographic data (longer DD and older ADO). However, factors associated with excellent response significantly differed depending on JIA category (anamnestic factors, number of involved joints, laboratory factors, and demographic factors). Background: Tumor necrosis factor inhibitors are highly effective and safe in treatment of juvenile idiopathic arthritis (JIA). Nonetheless, to select the optimal therapy and to achieve maximum therapeutic effect it is necessary to consider the individual characteristics of the patient. Adalimumab (ADA) is widespread use for mild and severe polyarticular JIA especially in the presence of uveitis, but there is lack of data about clinical and laboratory predictors of response to ADA in different JIA categories. Objectives: To identify clinical and laboratory parameters associated with Abstract AB0951 - Background: Recently due to application of interleukin (IL)-6 inhibitors prognosis for systemic juvenile idiopathic arthritis (sJIA) has significantly improved. 526 children with JIA are under monitoring in Chelyabinsk region, 42 children have sJIA. Tocilizumab is the drug of choice for sJIA treatment. It is registered within the Russian Federation for use in children older than 2 years. In Chelyabinsk Regional Children Hospital tocilizumab has been used for 5 years. Methods: 18 children (12 boys, 6 girls) aged from 2 to 17 (mean age 10.7 years) diagnosed with sJIA were under monitoring. Disease duration was from 6 months to 15 years (mean duration 6 years). JIA was diagnosed based on ILAR diagnostic criteria. SJIA was diagnosed in 16 children, sero-negative polyarthritis was diagnosed in 2 children. Tocilizumab was introduced intravenously every 2 or 4 weeks in dose of 12 mg/kg for children <30 kg or 8 mg/kg for children ≥30 kg. Therapy duration was from 3 months to 5 years (average duration 23 months). Assessment of disease activity and therapy efficiency was conducted in accordance with ACR pedi criteria. Nonparametric statistical methods were used to compare results. Results: Prior to tocilizumab use high disease activity was observed in all children. Average number of joints with active arthritis was 13,5 [6;15] VAS 84 [80; 90] . No eye lesions were found in children under monitoring. All 16 children with sJIA had fever, hepatosplenomegaly and lymphadenopathy, the rash had 11 children, polyserositis -8. In 5 children there was a complication in the form of a syndrome of macrophage activation. During the tocilizumab therapy a decrease in disease activity was observed Clinical disease remission (according to ACR pedi criteria-≥90%) was observed in 11 patients after 6-9 months of treatment. Remission duration up to now is from 3 months to 4 years. Efficiency according to ACR pedi criteria is 70% in 6 children, 50% in 1. The drug was well-tolerated. Undesirable effect such as allergic skin reactions were observed only in one child. In one child the lack of efficiency produced by switching to canakinumab. Drug was cancelled in 3 patients due to long-term remission (3-4 years), but 2 of them after a year needed the resumption of therapy in connection with the aggravation of the disease. 
Conclusions

